2022 Sponsors
Please find all available sponsorship options for the 2023 Conference here:
We would like to thank the sponsors of the 10th International mRNA Health Conference:
Gold Sponsors
Acuitas Therapeutics is a private biotechnology company based in Vancouver, Canada that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). Acuitas Therapeutics partners with pharmaceutical and biotechnology companies, non-governmental organizations and academic institutes across the globe to advance nucleic acid therapeutics to the clinic and the marketplace. This includes research and development of vaccines to address malaria, tuberculosis, HIV and cancer, as well as the development of therapeutics in various other modalities, including genome editing and monoclonal antibodies. The company’s proprietary LNP technology has been proven as a highly effective delivery system, first approved for patients in ONPATTRO® with partner Alnylam Pharmaceuticals and, most recently, in the BioNTech/Pfizer COVID-19 vaccine COMIRNATY®.
Arcturus Therapeutics Holdings Inc. is a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.com.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.
About Cytiva.
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in 43 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing. Visit cytiva.com to learn more.
Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas of mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant allowing for clinical and commercial production at scale and unprecedented speed. Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Our Cambridge, MA based Immuno-epigenetics and Immunology teams are growing and seeking Scientists, Sr. Scientists and Research Associates to join their team.
NanoVation Therapeutics (NTx) is a private biotechnology company, founded in 2020, based in Vancouver, BC, Canada, developing technologies enabling next-generation gene therapies to address multiple diseases. For specific indications, NanoVation is partnered with local and international biotech companies to develop state-of-the-art delivery technologies for nucleic acid therapeutics.
MilliporeSigma, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. We provide solutions to help you overcome your mRNA research, development, manufacturing and LNP formulation challenges. With our broad portfolio of best-in-class products, our CDMO capabilities and a wide range of services, we can support all stages of your mRNA drug manufacturing process. Discover how our capabilities, technical expertise and regulatory know-how can help you improve process economics, accelerate time to market and mitigate risk.
Polymun Scientific GmbH
is a private Austrian company, located in Klosterneuburg, offering contract development and manufacturing of biopharmaceuticals as well as development and production of LNP and liposomal formulations. Its patented liposome/LNP technology allows efficient manufacturing of constantly high quality in small and large scale. Over the last 15 years, Polymun has guided LNP and liposomal formulations into clinical trials, amongst them DNA and different kinds of RNA formulations. A prominent example is Polymun’s contribution to the BioNTech/Pfizer Covid-19 vaccine. Polymun is an FDA- and EMA-inspected manufacturer conducting several own R&D projects. For more information, please visit www.polymun.com
Precision NanoSystems is a global leader in technologies, solutions and services for the development of lipid nanoparticle genomic medicines, including mRNA vaccines and therapeutics. We support (bio)pharma companies who are ushering in the next wave of genomic medicines in infectious diseases, cancer and rare diseases. We work with the world’s leading drug developers to understand disease and help create the therapeutics and vaccines that will define the future of medicine. Our mission is to accelerate the creation of transformative medicine that significantly impacts human wellbeing
From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech has supplied nucleotides and enzymes for mRNA production. We work with many pioneering mRNA
companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast with market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built
on our raw materials by ensuring best quality, high performance within narrow tolerances, andreliable delivery.
Remaining at the front of this fast-paced therapeutic space hinges not only on ideas and implementation, but also on speed and quality.
Your expertise is coming up with the idea and the implementation; as a long-standing global supplier, Roche CustomBiotech’s expertise in raw
materials can help you accelerate development and ensure high quality mRNA.
We help you strengthen your supply chain, ease transfers to manufacturing, secure continuous production,
and create consistently high-quality products.
https://custombiotech.roche.com/global/en/portfolio/mrna-therapeutics-raw-materials.html
Thermo Fisher Scientific supports developers and manufacturers of nucleic acid therapeutics and vaccines with a proven product portfolio that spans from discovery to development to global scale commercial production. Starting with therapeutic grade raw materials, we provide the products and services necessary to bring a nucleic acid therapeutic to market. Our portfolio includes products for in vitro transcription, oligonucleotide synthesis, purification, analytical and QC testing, single-use technologies, and comprehensive measurement and control solutions.
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, including NTPs and mRNA capping analogs. TriLink’s proprietary mRNA capping technology, CleanCap®, simplifies mRNA manufacturing by removing additional enzyme-dependent steps, resulting in higher capping efficiency and improved yields over traditional co-transcriptional capping methods.
TriLink’s CDMO solutions include a range of manufacturing grade products, from discovery-grade to a customizable GMPLink™ intermediate grade, to full GMP-grade with scale-up and technology transfer capabilities. TriLink operates quality systems in compliance with ICH Q7, GMP Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards.
TriLink continues to expand its cGMP capacity at its new headquarters in San Diego, California, with scale-up expertise and unique production capabilities of mRNA, oligonucleotides, and plasmid DNA for biopharmaceutical companies focused on therapeutic, vaccine, and diagnostic breakthroughs.
Silver Sponsors
Arranta Bio: One trusted expert, with you on your path to the patient
Arranta Bio provides novel solutions to clients for advanced therapy process development and manufacturing. Our expertise and ability to provide end-to-end solutions helps guide advanced therapeutic products through the clinical journey to the commercial. We focus on partnership and tailor our solutions to each company’s unique needs.
mRNA Vaccine Manufacturing Services: An integrated solution for mRNA vaccine manufacturing
mRNA platforms are reinventing how prophylactic and disease-targeted vaccines are delivered. Arranta Bio is helping advance the industry by combining the entire mRNA value chain under one roof. We provide a complete, end-to-end solution for developing and manufacturing plasmid, mRNA, colloidal delivery systems including lipid nanoparticles (LNP) and the injectable sterile drug product, enabling our partners to gain speed-to-market advantage with next-generation mRNA products.
Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large-scale production. In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. The company is part of Univercells Group, with the mission of ensuring that everyone has access to biologics everywhere in the world.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Vernal Biosciences is a fully integrated CDMO with a singular focus on manufacturing and formulating mRNA. Because science matters more than ever, we are inspired to accelerate the potential of mRNA through democratizing access to our expertise and unparalleled mRNA and LNP-mRNA platform technologies. Combined with phase-appropriate GMP, and control and quality systems, these technologies are an advanced manufacturing staging ground for your research, preclinical, and ultimately clinical development supply needs.
Bronze Sponsors
ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc., the first drug discovery platform company in Japan, and Arcturus Therapeutics, US-based global late-stage clinical messenger RNA (mRNA) medicines company.
ARCALIS aims to develop the integrated mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including Arcturus, other pharmaceutical companies, biotech companies, and academic institutes worldwide. The new facility in Minami-soma (Fukushima prefecture) will have state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticalsARCALIS also provides the integrated drug discovery service, including mRNA design, synthesis, evaluation, LNP formulation, and in vitro/in vivo evaluations. Through this service, customers can instantly obtain the in vivo expression-proven mRNA-LNP and quickly validate the concept (go/no-go decision).
Catalent Biologics provides advanced technologies and solutions for protein and gene therapy development, manufacturing and clinical supply. With technology platforms including GPEx® cell line engineering, SMARTag® bioconjugation and AAV viral vector expression combined with comprehensive analytical services and fill/finish supply, Catalent Biologics is your premier partner for clinical and commercial success.
CerTest VACCINES is a division of CerTest Biotec, directed to the development of mRNA vaccines.
Since its founding back in 2002, CerTest Biotec has been mainly focused on the development of innovative solutions for the diagnosis of a wide range of infectious diseases. The extensive work behind each and all of these developments has enabled us to acquire vast experience in a great variety of pathogens, such as RSV, Influenza or SARS-CoV-2.
This previous knowledge put us in an enviable position, as it provides us with a close understanding of these diseases. Thus, our goal is to develop RNA vaccines against these kinds of pathogens, a scope that could be broadened to other applications, such as cancer immunotherapy. The advances resulting from our efforts will hopefully be a positive contribution to this field and help face other potential threats in the future.
Codexis is a leading enzyme engineering company leveraging its proprietary technology to discover and develop novel, high performance enzymes for Life Science applications. Our high-performance enzymes are engineered to meet the challenges of manufacturing large quantities of full-length mRNA. The result is a more efficient and scalable process, attributed to greater yields of capped mRNA with reduced impurities. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics offering spans discovery to clinic and fill-finish services across monoclonal antibodies, recombinant proteins and mRNA therapeutics. Our scientific and process experts, and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics.
To learn more visit us at curiaglobal.com/biologics
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010.
Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments.
Eurogentec has production sites in Europe and United States of America.
The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines).
Evonik, a global CDMO, provides drug delivery technologies, excipients, API manufacturing, intermediates, amino acids and derivatives for pharmaceuticals. Core competencies extend across chemistry, biotechnology, process engineering, with a global network of manufacturing and lab sites.
We are a leading CDMO for complex parenteral drug products, including LNPs formulations for mRNA delivery, gene therapies and nanomedicines. Services include the formulation, process development, GMP manufacturing, and aseptic filling for drugs that utilize lipid-based or polymeric delivery technologies. Custom manufactured GMP lipids and PhytoChol® vegetal-derived cholesterol for injectable lipid nanoparticle (LNP) formulations are offered. Other excipients for parenteral drugs include the market leading RESOMER® and LACTEL® portfolio of bioresorbable polymers for extended release and CMO services for proprietary excipients. LIPEX® Flow extruders are offered for liposome manufacturing at all scales.
Evonik’s integrated portfolio of excipients and CDMO services has helped transform small molecules, peptides, proteins, nucleic acids, synthetic vaccines, and other drug substances into high-performance medicines. Regardless of the stage of drug development, our expertise, technologies, high-quality sites, and strong regulatory track record can help reduce project risk and improve supply security.
Discover how Evonik can help accelerate speed to market and optimize drug performance.
FUJIFILM Corporation is going to transform into a healthcare company through leveraging fine-chemical technologies cultivated in photo-films’ manufacturing, such as organic-chemistry and nanotechnologies. Based on these assets, we have started one-stop CDMO service from bench top formulation research to GMP manufacturing for lipid nanoparticles utilizing Fujifilm’s proprietary ionizable lipids.
Hongene Biotech Corporation was established in 1998 as a R&D organization and has since become a manufacturer with state-of-the-art facilities in the fields of nucleosides, nucleotides and phosphoramidites.
The company, which initially operated in Shanghai, China, now has subsidiaries and laboratories in the US, Germany and Japan. Hongene supplies only the best quality and competitively priced products to customers around the world. Through collaborations with pharmaceutical diagnostic and biotechnology companies, Hongene is continuously developing new products in this area of science.
At Hongene our experts are also happy to offer custom synthesis products essential for your R&D, helping to bring your products to market more efficiently. Through continuous innovation, improvement of manufacturing technologies, the tightest quality control and devoted technical team and services, we aim to help our customers to achieve their goals efficiently and economically.
InProcess-LSP is a highly innovative organization providing full Process Analytical Technology (PAT) method and instrument development services. It was founded in 2014 and is based at Pivot Park High Tech Pharma campus in The Netherlands.
Being experts in nanoparticle size characterization, they are the inventors of the NanoFlowSizer: a unique, non-invasive nanoparticle size instrumentation for real-time measurement. With the NanoFlowSizer, nanoparticle sizing takes place within 10s, enabling continuous real-time in flow analysis.
The NanoFlowSizer thanks its unique properties of being the only instrument capable of measuring particle size and size distribution of turbid nanosuspensions in flow, without the need for sample treatment or dilution.
The technology is based on Spatially Resolved Dynamic Light Scattering (SR-DLS). SR-DLS allows particle size characterization in process flows and can measure highly turbid suspensions without dilution.
The InProcess-LSP team has a great experience and interest in PAT science and a strong background in process and product development. Our analytical capabilities include low-coherence interferometry; UV/VIS, NIR and Raman Spectroscopy, high-resolution microscopes and NIR Imaging.
LGC Axolabs is a world leading service provider in oligonucleotide- & mRNA-based therapeutics. We are the single organisation to deliver best solutions for nucleic acid therapeutics’ development, ranging from lead ID, across all clinical stages, to commercial supply.
For mRNAs, Axolabs’ portfolio includes uHPLC-MS based methods to confirm the identity, capping efficacy, poly(A)tail length & polydispersity characterisation, mRNA integrity & purity. LNP formulations can be characterised for size, polydispersity, surface charge & payload encapsulation together with quantitative analysis of lipid & mRNA-composition. All analytical services can be conducted under GMP to support Drug Substance and Drug Product release as well as ICH compliant stability studies.
Services to analyse pharmacological properties of mRNA formulations include in vitro & in vivo analysis of activity & safety, pharmacokinetics & biodistribution to support GLP-Tox studies as well as clinical trials.
For over 40 years, New England Biolabs, Inc. has led the industry in the discovery and production of molecular biology reagents. In addition to products for genomic research, NEB continues to expand its product offerings into areas related to PCR, gene expression, sample prep for next gen sequencing, cellular analysis, synthetic biology and RNA analysis. NEB is also supporting customers in the development of diagnostics and vaccines for SARS-CoV-2.
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF’s LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.
Organix (part of the Symeres Group) is the foremost lipid provider, enabling our clients to bring new therapeutics to the market. Our mission is to provide high quality lipids and lipoids for use in LNP delivery of RNA and DNA modifiers. We are continually adding new lipids and lipoids to our arsenal. Organix is a CRO focused on Synthetic Organic and Medicinal Chemistry located in the United States. Organix is recognized internationally as a premier provider of high-quality lipids and outstanding services at the discovery end of the drug development pathway. Organix operates a state-of-the-art facility, staffed by highly skilled Ph.D. organic chemists. Organix retains no rights to discoveries or inventions. We provide Custom Synthesis in all structural classes, Design and Synthesis of NCE, SAR Studies, Hit-to-Lead Studies, and Process Development, Design and Synthesis of Drug Conjugates.
ST PHARM is a global oligonucleotide and mRNA CDMO for gene therapy. Since 1983, ST PHARM offered excellent custom manufacturing services of oligonucleotides and small molecule APIs to meet client’s high expectation for their use in pharmaceutical development in compliance with cGMP requirements. Based on in-depth knowledge of manufacturing from nucleoside to oligonucleotide, ST PHARM expanded its business capability to manufacturing polynucleotide, the mRNA.
ST PHARM has established mRNA technology platform and provides fully integrated one-stop service from IVT synthesis to LNP formulation. Especially, the company owns a novel 5’-capping reagent known as SmartCap®, which is a library of capping analogs. ST PHARM therefore provides a screening service of SmartCap library which identifies and selects the most suitable capping analog with highest efficiency depending on client’s mRNA sequence and ORF. The company also developed its own LNP technology, SmartLNP®, to provide more potent and efficient mRNA delivery in human. ST PHARM also has a capability and capacity of manufacturing key raw materials for SmartCap, SmartLNP and various lipids for other LNP formulations as well as mass production in both GMP and non-GMP grade. The company will provide all materials and services required from R&D stage at high quality and competitive price.
Currently, ST PHARM’s COVID-19 mRNA vaccine program is in clinical phase 1 in both South Korea and South Africa and in progress of developing pan-coronavirus ‘mock-up’ vaccine to fight against multiple COVID-19 variants.
ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. Described by Nature as one of the “Seven Technologies to Watch in 2022,” ReCode’s SORT LNP platform is an innovation beyond the lipid delivery system used by the mRNA COVID vaccines and novel RNA and gene correction therapeutics.
ReCode’s SORT LNPs are engineered with a biochemically distinct fifth lipid to help the body “sort” and direct the LNPs to other targeted organs such as the lung and spleen with the ability to bypass the liver, if desired. ReCode’s SORT LNP platform is further distinguished by its versatility in both mode of administration and the diversity of genetic cargo that can be delivered. Together, these qualities offer vast opportunities to address a wide range of unmet medical needs through a precision medicine approach that delivers the right medicine to the right organs and cells using the optimal mode of administration.
ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics include its lead programs focused on primary ciliary dyskinesia and cystic fibrosis. The company plans to expand its pipeline of genetic medicines to include central nervous system, lung, liver, and oncology indications.
For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
Wacker Biotech is “YOUR MICROBIAL CDMO” – partner of choice for process development and commercial manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live microbial products, messenger ribonucleic acid (mRNA) and plasmid DNA (pDNA)) based on microbial systems. Developed over decades, our plug-and-play platform for pDNA is suitable for manufacturing R&D supplies (non-GMP) up to scale-up to full GMP-compliant production.
Our integrated service portfolio covers molecular biology, process- and analytical development as well as GMP manufacturing of biologics for clinical and commercial supply. Wacker Biotech maintains four GMP-compliant production plants in Amsterdam (The Netherlands), San Diego (US) and in the German cities of Jena and Halle.
Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly owned subsidiaries of Munich-based Wacker Chemie AG. For more information, visit: wacker.com/biologics
Xpress Biologics is a dynamic and customer-oriented Contract Development and Manufacturing Organization (CDMO) specialized in the development of manufacturing processes based on microbial expression systems (E. coli and P. pastoris) and the production of Biologics (recombinant proteins, antibody fragments and plasmid DNA) for the therapeutic, vaccine and diagnostic markets.
Our unique DNA manufacturing platform allows the production of up to 20 g of R&D, HQ (High Quality) and, as of 2023, GMP grade plasmid DNA. Our DNA manufacturing process has been shown to be efficient for the production of many types of plasmid DNA including small and large DNA backbones, low and high-copy number vectors, supercoiled plasmids including LTR or ITR for the manufacturing of LV and AAV, and linearized plasmid including a polyA tail for the manufacturing of mRNA.
Ziphius Vaccines is a biotechnology company focused on the development of self-amplifying RNA-based (saRNA) vaccines and therapeutics. Its powerful saRNA and carrier technology platform is designed to allow for a higher and prolonged protein expression at lower doses with reduced toxicity. Based on this platform the Company has a broad pipeline of vaccines for the prevention of infectious diseases and therapies for the treatment of rare genetic disorders. Based in Ghent, Belgium, Ziphius’ team consists of 50 highly skilled experts and is backed by leading academics and knowledge institutes.
For more information, visit www.ziphius.org, and follow us on LinkedIn.
